Skip to content

Our Pipeline

WE ARE DEDICATED TO ADVANCING A NOVEL CLASS OF CONDITIONALLY-ACTIVATED PROINFLAMMATORY IMMUNE MODULATORS INTO CLINICAL DEVELOPMENT

CANDIDATE
Discovery
IND-Enabling
Phase 1
Phase 2
WTX-124
  • WTX-124 is a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINETM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-2 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in multiple tumor types.
  • WTX-124 is designed to include maintenance of full IL-2 potency, high affinity blockade of IL2 - IL2Rβ/IL2Rγ interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
  • In preclinical studies, WTX-124 exhibits excellent anti-tumor activity with a favorable pharmacokinetic and tolerability profile. Efficacy is driven by the differentiation, activation and expansion of T effector and memory lymphocyte immune responses.
  • We are currently enrolling patients in a first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced solid tumors. For more information on this study, visit clinicaltrials.gov (Identifier NCT05479812).
WTX-330
  • WTX-330 is a systemically delivered, conditionally activated Interleukin-12 (IL-12) INDUKINETM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-12 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors.
  • WTX-330 is designed to include high affinity blockade of IL-12 – IL-12R interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
  • In preclinical studies, WTX-330 exhibits excellent anti-tumor activity and a favorable pharmacokinetic and tolerability profile. Robust anti-tumor activity is mediated through stimulation of innate and adaptive antitumor immune responses - dendritic cell maturation and cross-presentation, Th1 differentiation and amplification of antitumor T effector cell responses.
WTX-613
Licensed by Jazz Pharmaceuticals
  • WTX-613 is a systemically delivered, conditionally activated Interferon alpha (IFNα) INDUKINETM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IFNα therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors.
  • Our INDUKINETM molecule is designed to include high efficiency blockade of IFNα – IFNR interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
  • In preclinical studies, WTX-613 exhibits robust anti-tumor activity mediated through stimulation of a type I interferon immune response with excellent pharmacokinetics and tolerability.
Discovery
Programs
  • We apply our PREDATORTM protein engineering technology platform to identify, design, optimize and validate new immuno-oncology, autoimmune and inflammatory disease product candidates.

Expanded Access Policy:

Expanded access, or compassionate use, is the use of an investigational product prior to regulatory approval and outside of a clinical trial. Werewolf does not currently have an expanded access program or compassionate use program for any of our investigational products. We understand that for people living with cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trials is the best path to meet our goal of providing new treatments to patients with cancer. We encourage any person with cancer interested in gaining access to our investigational therapies to consult their physician(s) regarding the possibility of participating in one of our clinical trials.